Condition: Neoplasms, Lung · Sponsor: GlaxoSmithKline
In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancer's ability to grow and spread. This study specifically aims to evaluate how well Ris-Rez works in treating relapsed SCLC compared to standard treatment topotecan, by checking whether Ris-Rez makes cancers smaller or disappear completely and if it helps participants live longer. The study is also assessing whether Ris-Rez is safe and tolerated well by participants compared to topotecan and provide a better understanding of the main side effects of both drugs. Participants with relapsed SCLC will be randomly divided into two groups: one group receiving Ris-Rez and the other receiving topotecan.
This description comes directly from the study's public registry record.
US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Mar del Plata, Buenos Aires, Argentina | Recruiting |
| GSK Investigational Site | Buenos Aires, Argentina | Recruiting |
| GSK Investigational Site | Ciudad Autonoma de Buenos Aire, Argentina | Recruiting |
| GSK Investigational Site | Ciudad Autonoma de Buenos Aire, Argentina | Recruiting |
| GSK Investigational Site | Rosario, Argentina | Recruiting |
| GSK Investigational Site | Vicente López, Argentina | Recruiting |
| GSK Investigational Site | Blacktown, New South Wales, Australia | Recruiting |
| GSK Investigational Site | St Leonards, New South Wales, Australia | Recruiting |
| GSK Investigational Site | Nedlands, Western Australia, Australia | Recruiting |
| GSK Investigational Site | Barretos, Brazil | Recruiting |
| GSK Investigational Site | CuritibaPR, Brazil | Recruiting |
| GSK Investigational Site | Florianópolis, Brazil | Recruiting |
+ 108 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07099898